MGMT and laryngeal carcinoma: To establish a possible function for such epigenetic modifications of the MGMT gene in laryngeal carcinogenesis, the present report analyzed MGMT mRNA expression levels, DNA methylation status, and the levels of promoter region di-methyl-H3K9 (H3K9me2), H3K4me2 and acetyl-H3K9 (H3K9ac) following DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine (Aza) and/or trichostatin A (TSA) treatment of laryngeal carcinoma HEp-2 cells.